Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) issued to Enveric US Patent No. 12,605,361 (the '361 patent), titled, “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company's EVM301 Series of molecules bei.